Palbociclib-d8

• Description :

  Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

• Product Name Alternative :

  PD 0332991-d8

• UNSPSC :

  12352005

• Hazard Statement :

  H341, H361, H373, H411

• Target :

  CDK; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Cell Cycle/DNA Damage; Others

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  99.84

• Solubility :

  DMSO : 1mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 8.33 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 80°C)

• Smiles :

  O=C1N(C2=NC(NC3=NC=C(C=C3)N4C([2H])(C([2H])(NC([2H])(C4([2H])[2H])[2H])[2H])[2H])=NC=C2C(C)=C1C(C)=O)C5CCCC5

• Molecular Formula :

  C24H21D8N7O2

• Molecular Weight :

  455.58

• Precautions :

  H341, H361, H373, H411

• References & Citations :

  [1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3 (11) :1427-38.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• Isoform :

  CDK4; CDK6

• CAS Number :

  [1628752-83-9]